Novartis’ Cholesterol-Lowering Drug Leqvio Gains FDA Approval

By PacConAdmin | December 23, 2021

The FDA has approved Novartis’s new drug application (NDA) for its cholesterol-lowering drug Leqvio (inclisiran) after rejecting the NDA a year ago because of manufacturing concerns.
Source: Drug Industry Daily

Posted in Drug Industry Daily